BTG International backs coeliac disease JV
28 October, 2003 by Melissa TrudingerA vaccine for coeliac disease is the focus of a joint venture between the Royal Melbourne Hospital, Melbourne Health and the Walter and Eliza Hall Institute of Medical Research (WEHI), in a project that has the backing of international VC group BTG International.
EpiTan reports "outstanding" results for Melanotan
28 October, 2003 by Graeme O'NeillMelbourne biotech EpiTan Ltd (ASX: EPT) has announced "outstanding" results from the Phase IIb clinical of its experimental tanning drug Melanotan - and says the data could be the subject of new patent applications.
Gradipore to refocus on commercialising its technology
28 October, 2003 by Melissa TrudingerAfter several tumultuous days that saw almost the entire board of directors replaced, bio-separations company Gradipore said today that it plans to focus on commercialising its technology for large-scale separations.
C3, Equipmed sign distribution agreements
27 October, 2003 by Melissa TrudingerPerth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.
Panbio announces alliance with Adaltis
24 October, 2003 by Melissa TrudingerDiagnostics company Panbio has announced a strategic alliance with Canadian-based medical diagnostics instrumentation group Adaltis to develop automated diagnostic products.
Third patient implanted with Ventracor device
23 October, 2003 by Melissa TrudingerVentracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
AtCor to enter US market
23 October, 2003 by Melissa TrudingerSydney-based devices company AtCor Medical is readying itself to make a major push into the US market with its range of cardiovascular diagnostic devices.
Virax wins US bioterrorism job
22 October, 2003 by Melissa TrudingerVirax (ASX:VHL) has received approval from the US State Department to participate in a collaboration to develop a modified smallpox vaccine.
Prima subsidiary claims arthritis treatment find
22 October, 2003 by Graeme O'NeillPrima BioMed (ASX:PRR) subsidiary Arthron believes it has found a new way of blocking the inflammatory reaction responsible for the crippling autoimmune disease rheumatoid arthritis.
Benitec claims 'multiple warhead' RNAi breakthrough
22 October, 2003 by Melissa TrudingerBenitec (ASX:BLT) has developed technology allowing simultaneous disabling of multiple genes through RNA interference.
Old fence to some, goldmine to BioProspect
21 October, 2003 by Graeme O'NeillAn ancient fence, its posts hewn from local trees, caught Matt Kealley's eye during a bioprospecting expedition in north Queensland's monsoonal woodlands a few years ago.
Visiomed receives TGA approval for MicroDERM Hair
21 October, 2003 by Melissa TrudingerPerth-based devices company Visiomed (ASX:VSG), formerly known as Xcell Diagnostics, has received TGA approval for a hair analysis system which uses the same computerised image analysis platform technology as its skin cancer diagnostic system.
AustCancer to launch new products in US market
20 October, 2003 by Melissa TrudingerAustralian Cancer Technology (ASX:ACU) has completed the acquisition of a range of nutraceuticals designed specifically for cancer patients undergoing treatment.
NZ biotech welcomes govt's GM decision
20 October, 2003 by Graeme O'NeillNew Zealand's biotechnology industry will emerge into the sunlight next week, after the NZ Parliament voted decisively to end the nation's moratorium on field trials of genetically modified organisms (GMOs).
Investment opportunities: The next big thing
17 October, 2003 by Melissa TrudingerMelissa Trudinger asks industry insiders where the next big investment opportunities will come from -- and identifies a few other likely chances.
